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ABSTRACT 
Atrial fibrillation (AF) is the most common cardiac arrhythmia and the major risk factor for 
thromboembolic stroke. Effective treatment with the oral anticoagulant (OAC) warfarin has 
been available for decades. However warfarin treatment is complicated, and demands dose 
adjustments and regular monitoring. Warfarin also increases the risk for bleeding, especially 
intracranial bleeding which is rare but often fatal. Undertreatment of AF with OACs has long 
been a global problem and it has been common to use low-dose aspirin (ASA) instead, 
despite evidence of poor efficacy.  
Several new directly acting oral anticoagulants (NOACs) have been introduced in routine 
care based on promising results from randomised trials – the first being dabigatran in 2011, 
followed by rivaroxaban in 2012 and apixaban in 2013. The introduction of these drugs has 
brought hope of facilitating OAC treatment, increasing the proportion of patients treated, and 
possibly also improving the effectiveness and/or safety of treatment.  
This thesis is based on four population based epidemiological studies describing the 
antithrombotic treatment of AF before and after the introduction of NOACs in the Stockholm 
health care region using the health registry of the Stockholm health care region, 
Vårdanalysdatabasen (VAL).  
Study I-II describe the entire AF population in the region, including demographics, risk 
stratification, treatment, and outcomes before the introduction of NOACs. Study III-IV 
compare treatment persistence, adherence, effectiveness, and safety of different 
antithrombotic treatments. 
The analyses show that undertreatment was common prior to the introduction of NOACs, 
but many of the patients without anticoagulant treatment were old, with complicating co-
morbidities, high bleeding risk and a poor prognosis in addition to a high risk of ischemic 
stroke. With NOACs there was a dramatic increase in the number of AF patients in the 
registries and a substantially larger proportion of the patients received OAC treatment. 
NOACs now dominate new treatment initiations, while warfarin has decreased substantially. 
In routine care warfarin and apixaban was associated with better persistence than dabigatran 
or rivaroxaban.  Adherence with OAC treatment was high (>90%), and slightly better with 
the once daily regimen of rivaroxaban than the twice daily regimens of apixaban and 
dabigatran. NOAC treatment had similar or better effectiveness and safety compared to 
warfarin treatment, with similar outcomes among the elderly (≥80 years) and patients with 
previous severe bleeds. NOACs were associated with fewer intracranial bleeds, but more 
gastrointestinal bleeds. The advantages with NOAC treatment were most pronounced with 
standard dosing in patients under the age of 80, and with reduced doses in patients aged 80 
and above. 
  
In conclusion, this thesis shows improvements in the management of AF in the Stockholm 
health care region and confirms that NOACs are attractive antithrombotic treatments for AF 
patients in routine care. More research is needed to further optimize the use of NOACs. 
  
 
SAMMANFATTNING PÅ SVENSKA 
Förmaksflimmer är den vanligaste rytmrubbningen i hjärtat och samtidigt den viktigaste 
riskfaktorn för embolisk hjärninfarkt. Det har funnits effektiv behandling med 
blodförtunnande läkemedel – antikoagulantia - sedan många decennier. Det i Sverige 
dominarande läkemedlet är warfarin. Tyvärr är warfarin ett komplicerat läkemedel som 
kräver dosjusteringar och regelbundna blodprov. Warfarin ökar också risken för blödningar, 
speciellt intrakraniella blödningar som ofta är dödliga. Underbehandling med antikoagulantia 
har länge varit ett globalt problem med många samverkande orsaker och det har varit vanligt 
att i hög utsträckning använda acetylsalicylsyra istället, trots dokumenterat sämre effekt.  
Flera nya direktverkande antikoagulantia (NOAK) har introducerats i sjukvården baserat på 
lovande resultat från randomiserade kliniska prövningar – de första var dabigatran 2011, 
rivaroxaban 2012 och apixaban 2013. Introduktionen av dessa läkemedel har inneburit hopp 
om att underlätta antikoagulantiabehandling, öka andelen patienter med förmaksflimmer som 
får adekvat behandling, och möjligen också förbättra effektivitet och/eller säkerhet vid 
behandling. 
Den här avhandlingen baseras på fyra populationsbaserade epidemiologiska delarbeten som 
beskriver den antitrombotiska behandlingen av förmaksflimmer före och efter introduktionen 
av NOAK i Stockholms Läns Landsting. 
Studie I-II beskriver hela förmaksflimmerpopulationen i Stockholms Läns Landsting, 
inkluderande demografi, riskstratifiering, behandling och utfall innan introduktionen av 
NOAK. Studie III-IV jämför behandlingspersistens, följsamhet till ordination, effektivitet och 
säkerhet mellan olika typer av antitrombotisk behandling.  
Analyserna visar att underbehandling var vanligt innan introduktionen av NOAK. Många 
av patienterna utan antikoagulantiabehandling var gamla med komplicerande samsjuklighet, 
hög blödningsrisk och dålig prognos, utöver en hög risk för ischemisk stroke. Introduktionen 
av NOAK innebar en dramatisk ökning i antalet patienter med förmaksflimmer som kunde 
identifieras i registren och en klart högre andel behandlades med antikoagulantia. NOAK 
dominerar nyinsättningarna och warfarin har minskat kraftigt. I rutinsjukvården var warfarin 
och apixaban associerade med högre persistens än rivaroxaban eller dabigatran. Följsamheten 
till ordination verkade vara något bättre med det endoserade rivaroxaban än de tvådoserade 
apixaban och dabigatran. NOAK verkade vara lika eller mer effektivt och säkert än warfarin. 
NOAK var associerat med lägre förekomst av intrakraniella blödningar men fler 
gastrointestinala blödningar. Fördelarna med NOAK-behandling var mest framträdande med 
standarddos hos patienter under 80 år och med dosreduktion hos patienter som var 80 år eller 
äldre.  
  
Sammanfattningsvis visar denna avhandling förbättringar i vården av förmaksflimmer i 
Stockholms Läns Landsting samt bekräftar att NOAK fungerar väl som antitrombotisk 
behandling i rutinsjukvård. Mer forskning behövs för att ytterligare förbättra användningen 
av NOAK.  
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1 INTRODUCTION 
Drugs are an increasingly important part of health care, to either treat symptoms or 
underlying causes of disease, or to prevent disease. Despite the substantial advancements in 
drug treatment and increases in health and life expectancy in the last century there are still 
many unmet needs and challenges for the improvement of drug therapy [1]. As diagnostic 
opportunities and treatments improve, the expectations and demands increase. One can even 
say that the improvements in health and life expectancy create new and more complicated 
medical challenges due to the multimorbidity and polypharmacy associated with increasing 
age [2].  
It is well documented that compliance to treatment guidelines often is inadequate and that 
many patients lack efficient evidence based treatment with medicines [3,4]. There are many 
possible reasons for this, including disturbing side-effects [5,6], lack of motivation resulting 
in low adherence to preventive drug treatments without symptomatic relief [6], high 
prevalence of relative or absolute contra-indications in target populations [7], and slow 
implementation of guidelines in health care [8].   
New drugs are introduced to address unmet needs of varying importance, and to facilitate 
treatment and adherence to guidelines. According to reviews, however, only 10-15% of new 
drugs provide substantial advantages compared to older treatments [9-11]. In France it has 
been claimed that less than 4% of new drug indications or new indications for existing drugs 
really provide real therapeutic advantages [12,13].  
From the clinicians point of view there are several problems with the randomized controlled 
trials providing the documentation for the registration of new drugs [14,15].  They may have 
sample sizes that are too small to fully assess the safety of drugs [15,16] or they may be so 
large that they result in statistically but not clinically significant treatment effects. The 
follow-up may be too short to show long-term benefits or risks [15,16]. Clinical trials are 
performed in settings which differ from routine care, with very well informed and motivated 
patients, and with much closer follow-up than that provided for the usual patient [15]. 
Importantly, patients in clinical trials are selected and may underrepresent or exclude 
vulnerable patient groups, especially elderly patients with multiple comorbidities [14,15]. The 
dosages used in the studies may also differ from those later used in routine care [15]. For 
these reasons the introduction of new drugs in routine care has to be regarded as another, 
fourth phase in the clinical and scientifical development of new therapies.    
In Sweden, regional Drug and Therapeutics Committees continuously assess the evidence 
for new treatments in relation to standard treatments and issue recommendations with high 
impact on drug treatment patterns [17,18]. Structured introduction of new drugs with possible 
health care benefits but associated with large costs is growing in importance [19]. Registry 
based studies provide the possibility to investigate the introduction of new drugs from 
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different angles and to assess the appropriateness of prescriptions. Other possibly more 
clinically meaningful outcomes can also be assessed [14]. Independent comparative 
effectiveness studies provide additional validation of the benefit and risks of new drugs in 
routine care [15]. Pharmacoepidemiologic registry based studies on large populations 
representative of routine care demand only limited resources and can be conducted rather 
fast. They may provide valuable information on effectiveness and safety in routine care and 
provide information on treatment results in vulnerable subgroups that have not been 
investigated in the randomized trials. However, they suffer from several methodological 
problems which are discussed in Chapter 6.1 [20]. 
1.1 ATRIAL FIBRILLATION 
1.1.1 Etiology 
The etiology of atrial fibrillation (AF) is multifactorial. AF often co-exists with numerous 
cardiovascular and other conditions [21-28], but the cause and effect are not always easy to 
distinguish [24-26]. AF also evolves in parallel with other conditions, which might be 
involved in the evolution of AF [26]. Associated conditions might lead to the development of 
AF through four general types of mechanisms [27]: ectopic firing and re-entry mechanisms 
caused by dysfunction of ion channels, abnormalities of intracellular Ca
2+
-handling, structural 
remodeling, or dysregulation of the autonomic nervous system [27]. AF itself also causes 
remodeling; this might explain the common progression from paroxysmal to permanent AF 
[29]. Several of the associated conditions, such as hypertension, heart failure, and diabetes are 
also associated with an increased risk for ischemic stroke in AF-patients [28,30,31].   
The most important risk factors for AF are age, hypertension, diabetes mellitus, and heart 
failure [26]. Increased age might lead to AF because of fibrosis and age-dependent loss of 
myocardial cells in the atria [26,27,32], but also due to other age related disorders [21,26]. 
Hypertension is common and an important risk factor, with higher blood pressure increasing 
the risk of AF and its complications [26,27]. Diabetes mellitus is found in 20% of AF 
patients, and might lead to disturbances of the atria [21,26,27]. Heart failure might cause AF, 
but be also a consequence of acute AF with tachycardia or permanent AF [24-27]. 
Symptomatic heart failure is very common in AF patients and can be found in approximately 
30% [21-23]; conversely, AF has a prevalence of 30–40% of in patients with heart failure.  
Coronary artery disease can be found in ≥20% of patients with AF [21-23,27]. Whether 
coronary artery disease leads to AF and in what ways AF might affect coronary perfusion are 
uncertain [21,33]. Valvular heart disease is common in patients with AF [21-23]. Mitral 
stenosis or regurgitation are strong risk factors for AF, possible due to distension of the atria 
[26], but AF also occurs in aortic valve disease [27]. Cardiomyopathies are generally rare, but 
can be found in 10% of AF patients [21-23,27]. Patients with atrial septal defects have AF in 
10–15% of the cases [21]. There are also other congenital heart defects that increase the risk 
of AF [21,27].  
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Subclinical thyroid disease might increase the risk for AF [26]. Obesity is common with a 
prevalence of approximately 25% in AF patients [21,23], and seems to increase the risk of 
AF [26]. Sleep apnea may be a risk factor for AF. Possible causes are increased atrial 
pressure and size due to the apneas, or autonomic changes [21,26]. Chronic obstructive 
pulmonary disease has a prevalence of 10–15% in AF patients, and might be involved in the 
progression towards permanent AF [21,26]. Chronic renal disease affects 10–15% of patients 
with AF [21,26,27]. Renal insufficiency might also increase the risk of both ischemic events 
and bleeds [21]. 
1.1.2 Epidemiology 
AF is the most common arrhythmia with a prevalence that increases with age and that has 
been estimated to be approximately 2% of the adult population in several European countries 
[34] In Sweden a prevalence of 2.9% of the adult population above 20 years of age has been 
reported [32]. The prevalence was higher in men than in women in all age groups. The mean 
age was approximately 75 years (men 71.9 years, women 82.2). The prevalence increased 
with age with a peak of 14.3% at 84 years [32]. Approximately 40 % of the AF-patients are 
above 80 years of age in Stockholm; they have a high risk for stroke, and complicating co-
morbidities are also common [28,35]. There has been discussion about the prevalence of 
undetected asymptomatic atrial fibrillation. A large Swedish study found undiagnosed atrial 
fibrillation in 3.0 % of 75 year old Swedish citizens when screening with intermittent ECG 
recordings over 2 weeks [36]. 
1.1.3 Atrial fibrillation in the health care system 
Randomised trials as well as many observational studies have analysed selected patient 
groups, such as hospitalised patients or patients seeing cardiologists in selected centres 
participating in quality registers and clinical trials [30,31,37-45]. When new treatment 
alternatives are implemented in the health care system, such as non-vitamin K antagonist oral 
anticoagulants (NOACs) [37-39], it is important to remember that the pivotal trials leading to 
approval from the medical agencies have been conducted on relatively young patients, often 
with a good prognosis and without absolute or relative contraindications for warfarin 
treatment. Observational trials are therefore important to assess treatment effects in regular 
health care. Statistical methods are often used to reduce confounding and make the treatment 
groups comparable. However, assessments of patients from different parts of the health care 
system are important to evaluate the value of new treatments for all patients in routine care 
[35,46,47]  
Patients with a diagnosis of AF are common throughout the health care system given the 
advanced age of the patients and the high prevalence of co-morbidities [26,28,35]. There is 
reason to believe that AF patients in regular health care differ from patients in randomized 
trials and/or observational registries [28,35], and  population based studies describing the 
management of atrial fibrillation throughout entire health care systems have been lacking.  
Many earlier observational studies of treatment routines and the risks of suffering stroke or 
severe bleeding have been conducted in hospital settings [30,31,40-43], even though many 
AF patients are treated in primary care [35,48-50]. The incidence and prevalence of AF 
depends on the health records chosen to identify patients with the diagnosis. Importantly, co-
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morbidities included in the CHA2DS2VASc score may be missing without records from all 
healthcare providers, which could lead to underestimations of the stroke risk. Data from 
several consecutive years and derived from both inpatient care, specialist ambulatory care, 
and primary care are needed to accurately determine the prevalence of a certain disease when 
using healthcare registers [35,47,51].  
1.1.4 Cardioembolic stroke 
AF increases the risk of thromboembolism, especially embolic stroke. Antithrombotic 
treatment is often indicated for stroke prevention [21]. Traditionally, the risk for ischemic 
stroke was assessed using the risk scoring system CHADS2, but since 2010 the refined risk 
scoring system CHA2DS2VASc has been promoted instead [21]. 
CHADS2 score 
The previously used CHADS2 score was calculated by adding 1 point for age above 75 
years, 1 point each for a history of cardiac failure, hypertension, or diabetes, and 2 points for 
a history of TIA/ischemic stroke. The treatment of choice for individuals with high risk 
(CHADS2 ≥ 2) of thromboembolism was oral anticoagulants [52], while treatment was 
considered for individuals with moderate risk (CHADS2 = 1). 
CHA2DS2VASc score 
Since 2010 it is generally recommended that the thromboembolic risk of AF patients should 
be assessed by the CHA2DS2VASc risk scoring system (Table 1) [30,31,40,52]. According to 
the earlier ESC guidelines individuals with a score of 2 or more should be treated with an oral 
anticoagulant [52].   
The CHA2DS2VASc risk score has been validated in several large registry based 
observational trials. However, analyses from Sweden have showed that the c-statistics for the 
composite thromboembolic endpoint only rose from 0.66 when using CHADS2 to 0.67 with 
CHA2DS2VASc [30]. The results were almost identical in a similar Danish study [40]. With 
CHA2DS2VASc age ≥ 75 years counts as 2 (like a previous TIA/ischemic stroke), while age 
65-74 years counts as 1. Additionally, female sex and vascular disease count as 1 each. With 
CHA2DS2VASc a greater proportion of patients with atrial fibrillation had an indication for 
anticoagulant treatment during the time period of this thesis [28,30,31]. Thus, patients with a 
definite indication increased from 65% when the risk was scored with CHADS2 (score ≥ 2) to 
85% when scored with CHA2DS2VASc (score ≥ 2) [28].  
According to the ESC guidelines from 2010 and 2012 OAC treatment should be considered 
in AF patients with a CHA2DS2VASc score of 1 (unless female sex is the only contributing 
factor). OACs should also be used instead of aspirin [52]. Recommendations in the AHA 
guidelines from 2014 are more moderate regarding treatment in patients with a 
CHA2DS2VASc score of 1 [53]. This is supported by observational studies from Denmark 
and Sweden that failed to show any net clinical benefit of warfarin in individuals with 
CHA2DS2VASc scores 0-1, while there was a rising net clinical benefit with CHA2DS2VASc 
scores of 2 and above [41,42]. Other observational analyses addressing methodological issues 
in the definition of stroke have reached the same conclusion [54]. Also, aspirin-treated AF 
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patients with a CHA2DS2VASc score of 1 in randomized trials had an annual incidence of 
systemic thromboembolism of only 0.9 %. The authors considered the risk low enough to 
consider withholding OAC treatment [55].  
Risk assessments have in many studies been performed without access to diagnoses from 
primary care [30,31,41,42], which might lead to underestimation of the CHA2DS2VASc 
scores and overestimation of the benefit of treatment in low-risk patients. However, the 
debate is on-going whether to treat or not [56], and in Asia the risk seems to be higher than in 
Europe [57]. Age 65-74 is associated with the largest increase in relative risk for stroke in 
individuals with CHA2DS2VASc=1 (relative risk approximately 3), while other risk factors 
are only associated with small increases in relative risk (relative risk < 1.2) [52]. Therefore, it 
has been suggested that a CHA2DS2VASc score of 1 due to age 65-74 years, with a 
progressively increasing risk within the age span, should be considered an indication for 
anticoagulant treatment, while other factors are unlikely to confer a net clinical benefit [57]. 
The recently (October 2015) finalized Swedish guidelines [58] concur with the ESC 
guidelines from 2010 and 2012 and recommend OAC treatment for AF patients with 
CHA2DS2VASc scores of 2 and above and to consider treatment with a score of 1. However, 
these guidelines are even more restrictive against aspirin treatment which should not be used. 
In 2016 the cut-off for treatment of women in the European guidelines was changed, as 
women were considered to have a definite indication for anticoagulant treatment at 
CHA2DS2VASc scores 3-9, and a possible indication at a CHA2DS2VASc score of 2 [59]. 
The inclusion of female sex as a risk factor in the CHA2DS2VASc score although it does not 
affect the indication for treatment raises the question of the need of revising the risk scoring 
of AF patients [60]. As mentioned above the CHA2DS2VASc score does not improve the 
overall prediction compared to the older CHADS2 score, while it greatly increases the 
population eligible for treatment. The more restrictive indication for anticoagulant treatment 
in the new ESC guidelines raises the issue of possible overtreatment of low-risk individuals 
even further.  
Improved risk stratification incorporating biological biomarkers has been proposed as an 
alternative to the CHA2DS2VASc score for predicting stroke [61,62], and could possibly also 
be used to predict bleeding [63], but the clinical feasibility and usefulness of such an 
approach is still uncertain.  
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Risk factor 
CHADS2 
score 
CHA2DS2VASc 
score 
Congestive heart failure/LV dysfunction 1 1 
Hypertension  1 1 
Age >75 1 2 
Diabetes mellitus 1 1 
Stroke/TIA/thrombo-embolism 2 2 
Vascular disease  1 
Age 65–74  1 
Sex category (i.e. female sex)  1 
Maximum score 6 9 
Table 1 - CHADS2 and CHA2DS2VASc score [21] 
 
1.1.5 Bleeding 
Risks of bleeding should also be considered when deciding whether to treat with 
antithrombotic drugs or to withhold treatment [21,52]. Data regarding the prognostic impact 
of bleeding in patients with AF appear to be lacking, but lessons can be learned from the 
adverse prognosis seen in patients with acute coronary symptoms that experience major 
bleeding [64]. Major bleeding may act as a marker of adverse outcomes in frail patients; but 
might also cause poor outcomes directly (from blood loss; haemorrhagic shock; anemia 
leading to reduced tissue oxygenation, and activation of sympathetic, vasoconstrictive and 
prothrombotic mechanisms) or indirectly through the negative impact of transfusions and/or 
interruption of treatment and failure to resume it [64-66].  
The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile INR, elderly age >65 years, drugs/alcohol concomitantly) scale can be 
used to assess bleeding risk [21,52], but there are numerous other scores [67]. However, the 
risk for stroke and severe bleeding are often associated and the risk for stroke is usually more 
important for individual patients [28,41,42]. A HAS-BLED score of ≥3 is an indication of 
high risk. These high risk patients should be treated with “caution” and closer follow-up is 
warranted [21,52]. For practical purposes, reducing the risk of bleeding by attention to 
reversible risk factors should be the main focus when treating with antithrombotic agents 
[64]. As mentioned above, new methods for risk stratification including biological 
biomarkers might be used to assess the risk/benefit balance of both stroke and bleeding [61-
63].  
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1.2 ANTITHROMBOTIC TREATMENTS 
Despite solid documentation for warfarin and poor documentation for low-dose aspirin 
[68,69] several studies have suggested problems with undertreatment with OAC and 
overtreatment with aspirin in patients with AF [31,35,41-43,69]. The standard treatment for 
many years has been vitamin K-antagonists, such as warfarin, while low dose aspirin has 
been recommended as recourse when warfarin could not be used [68]. Analyses have shown 
that the proportion of patients treated with OACs started to increase already before the 
NOAC era [48].  
 
 Pivotal study 
publication year 
EMA-approval Swedish 
reimbursement 
Dabigatran 2009 April 2011 December 2011 
Rivaroxaban 2011 December 2011 October 2012 
Apixaban 2011 November 2012 May 2013 
Table 2 – The introduction of NOACs 
 
The introduction of NOACs since 2011 [37-39] (Table 2) has improved the possibility to 
provide adequate anticoagulant treatment of AF patients. With the introduction of NOACs 
more patients receive OAC treatment according to guidelines both internationally [70], and in 
Sweden (see Chapter 5.3). With the more aggressive treatment guidelines [52,53] 
overtreatment of low risk patients has also become an issue [35,54,57]. 
1.2.1 Warfarin 
Warfarin or other vitamin-K antagonists were the only available alternatives for oral 
anticoagulant treatment during 65 years. Warfarin decreases the synthesis of the vitamin-K 
dependent clotting factors II, VII, IX, and X thereby decreasing the conversion of fibrinogen 
to fibrin [71].  
Treatment with warfarin, as with all anticoagulant agents, implies balancing between risks 
for ischemic events and bleeding (Figure 1). Treatment with warfarin reduces the risk for 
stroke compared to both placebo and to aspirin according to meta-analyses of randomized 
trials [68]. Warfarin reduced the risk for stroke (ischemic and hemorrhagic) by 64% 
compared to placebo in an ITT-analysis; on treatment the risk was reduced by over 80 % with 
well managed warfarin treatment [68,72]. Compared to aspirin the relative risk reduction for 
stroke was 40% with warfarin (absolute risk reduction in primary prevention 0.7%, and in 
secondary prevention 7.0%), the risk of intracranial hemorrhage was doubled (absolute risk 
increase 0.2%), and all-cause mortality was reduced by 0.5% per year [68].  
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Figure 1 – Odds ratios for ischemic stroke and intracranial bleeding related to 
International normalized ratio (INR) [72]  
© 2006 by the American College of Cardiology Foundation, the American Heart Association, Inc, and the European Society of 
Cardiology. Reproduced with permission.  
With time the quality of warfarin treatment and the outcomes have improved [73], as well 
as knowledge on how to address potential problems with the treatment [64,72,74]. Bleeding 
during warfarin treatment is primarily managed by securing adequate circulation, local 
control (e.g. endoscopic treatment or surgical haemostasis), and erythrocyte transfusion. The 
anticoagulant effect can be reversed by administrating vitamin K intravenously. The INR will 
start to drop within 2 h and INR will be normalized within 12–16h. In the case of serious or 
life-threatening bleeding, immediate reversal can be achieved by the administration of 
prothrombin complex concentrates (PCCs) [64].  
The randomized BAFTA study addressed the question of whether to treat old patients in 
whom the doctors had reservations about anticoagulant treatment with warfarin or aspirin. 
The population was still selected since the physicians had the choice to exclude the frailest 
patients, and only a minority of the possibly eligible patients above the age of 75 years were 
included [75]. However, the results were clear. Warfarin treatment halved the risk of 
suffering any stroke compared to aspirin treatment without significant differences in bleeding 
or mortality in patients above the age of 75 [75].  
Yet there has been, and still is, reluctance to treat old and frail patients with OACs [69].  
1.2.2 Non-vitamin K antagonist oral anticoagulants (NOACs) 
 
With the introduction of NOACs [37-39] there are now more alternatives when choosing 
OAC treatment for AF patients and a possibility that more AF patients could be adequately 
treated. The directly acting thrombin inhibitor dabigatran received reimbursement in Sweden 
in December 2011 for treatment of AF. The directly acting factor Xa inhibitors rivoraxaban, 
and apixaban received reimbursement in October 2012 and in May 2013, respectively. The 
pharmacological properties of the three NOACs are further discussed below.  
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Table 3 – Study design of the NOAC pivotal trials [37-39] 
 
All three NOACs have demonstrated similar or better stroke prevention and similar or 
lower risk for serious bleeding compared to warfarin in multinational studies involving 6 000-
9 000 patients per treatment group and median follow-up times of 1.6-2 years [37-39] (Table 
3). The risk for intracranial hemorrhage was lower with all three NOACs, while 
gastrointestinal bleeding was more frequent with the standard dose of dabigatran (150mg x2) 
and with rivaroxaban; but not with apixaban [37-39] (Table 4). The quality of warfarin 
treatment in the comparator arms, measured as Time in Theraputic Range (TTR), has been 
highly variable between regions [37-39,76-78] (Table 3). Substudies have demonstrated that 
superiority of NOACs was found in centers and/or regions with poor TTR, while the results 
were similar in centers with optimal TTR and in Western Europe [76,78]. The mean TTRs 
were 75-80% in Sweden in all three pivotal trials, which is consistent with results from 
patients in the quality register Auricula [79]. However, quality registers like Auricula are only 
used in some regions and centers in Sweden, and the quality of warfarin treatment elsewhere 
remains less well documented. 
 
Study design Dabigatran (D) 
RE-LY [37] 
Apixaban (A) 
ARISTOTLE [39] 
Rivaroxaban (R) 
ROCKET-AF [38] 
No. of patients 18 113 18 201 14 264 
Age, years 71 (mean) 70 (median) 73 (median) 
Prior warfarin 50% 57% 62% 
Compared 
treatments 
D 150 mg x 2 
D 110 mg x 2 
Warfarin (INR 2-3) 
A (2.5-) 5 mg x 2 
Warfarin (INR 2-3) 
R (15-) 20 mg x 1  
Warfarin (INR 2-3) 
TTR, mean 64% 62%  55%  
Dose reduction Randomization 4.7% 20.8% (?) 
Follow-up, years 2.0 (median) 1.8 (median) 1.6 (median)  
CHADS2 score 
 
2.2±1.2 
32% CHADS2 = 0-1 
2.1±1.1 
34% CHADS2 = 1 
3.5±0.9 
0% CHADS2 = 0-1 
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Outcomes Dabigatran (D) 
RE-LY [37] 
Apixaban (A) 
ARISTOTLE [39] 
Rivaroxaban (R) 
ROCKET-AF [38]* 
Absolute outcomes vs. warfarin (%/year) 
Stroke/systemic 
embolism 
D110: 1.53 vs 1.69 
D150: 1.11 vs 1.69 
1.27 vs 1.60  2.1 vs. 2.4  
(on treatment)  
Hem. stroke  D110: 0.12 vs 0.38 
D150: 0.10 vs 0.38 
0.24 vs 0.47 0.26 vs 0.44 
(on treatment) 
Total död  D110: 3.75 vs 4.13 
D150: 3.64 vs 4.13 
3.52 vs 3.94 
 
1.87 vs. 2.21  
(on treatment) 
4.5 vs. 4.9 (ITT) 
Relative outcomes vs. warfarin (RR (95% CI)) 
Stroke/systemic 
embolism 
 
D150: 0.66 (0.53-0.82) 
D110: 0.91 (0.74-1.11) 
0.79 (0.66-0.95) 0.88 (0.75-1.03) 
according to ITT; 
0.79 on treatment 
Ischemisk or 
unspecified stroke 
D150: 0.76 (0.60-0.98) 
D110: 1.11 (0.89-1.40) 
0.92 (0.74-1.13) 0.94 (0.75-1.17) 
(ischemic only) 
Hemorrhagic 
stroke 
D150: 0.26 (0.14-0.49) 
D110: 0.31 (0.17-0.56) 
0.51 (0.35-0.75) 0.59 (0.37-0.93) 
Myocardial 
infarction 
D150; 1.38 (1.00-1.91) 
D110: 1.35 (0.98-1.87) 
0.88 (0.66-1.17) 0.81 (0.63-1.06) 
Death D150: 0.88 (0.77-1.00) 
D110: 0.91 (0.80-1.03) 
0.89 (0.88-0.99) 0.85 (0.70-1.02) 
Bleeds, serious  D150: 0.93 (0.81-1.07) 
D110: 0.80 (0.69-0.93) 
0.69 (0.60-0.80) 1.04 (0.90-1.20) 
Gastrointestinal 
bleeds, serious 
D150: 1.50 (1.19-1.89) 
D110: 1.10 (0.86-1.41) 
0.89 (0.70-1.15)  (3.2 vs 2.2%. p<0.001) 
Minor bleeds D150: 0.91 (0.85-0.97) 
D110: 0.79 (0.74-0.83) 
? ? 
*The primary comparisons in the ROCKET-AF trial were done on treatment, not according to intention-to-
treat (ITT) 
Table 4 –Absolute and relative outcomes in the NOAC pivotal trials [37-39] 
 
The optimal dosages of the NOACs remain unclear. For dabigatran the patients were 
randomized to either 150 mg twice daily or 110 mg twice daily in the RE-LY trial [37]. The 
approved standard dosage is 150 mg twice daily both in Europe and the US, but the 
recommendations regarding dose reduction differ. In Europe dose reduction to 110 mg twice 
daily is warranted in patients above the age of 80 years [80]. Dose reduction should also be 
considered in patients above the age of 75 years, in patients with moderate renal insufficiency 
or in patients with increased bleeding risk [80]. In the U.S.A. the 110 mg dose was not 
approved, and dose reduction should only be considered in patients with severe renal 
insufficiency (eGFR 15-30 ml/min); the recommended dose is then 75mg twice daily [81].    
For rivaroxaban the standard dosage is 20 mg once daily. Dose reduction to 15 mg once 
daily was recommended for patients with eGFR 30-49 ml/min in the ROCKET trial [38,82]. 
There is no published documentation regarding the proportion of patients with dose 
  19 
reduction, but 20.8% of the study population had reduced renal function (eGFR 30-49 
ml/min) [38]. 
Apixaban is recommended with the standard dosage 5 mg twice daily. The dosage should 
be reduced to 2.5 mg twice daily in patients with two of the following criteria: age ≥ 80 years, 
weight ≤ 60 kg, serum creatinine ≥ 133 µmol/L [83]. Only 4.7% of the patients in the 
ARISTOTLE trial received the reduced dosage [39]. 
Dabigatran has also been investigated in patients with mechanical valve prosthesis, with or 
without AF [84]. The trial was interrupted due to a higher incidence of stroke with 
dabigatran, despite higher dosages guided by plasma concentration measurements to 
guarantee therapeutic levels. Warfarin remains the only available treatment for these patients.   
Apixaban has demonstrated better stroke prevention without significantly more bleeding 
compared to aspirin in patients in whom the benefit of OAC treatment was unclear to the 
physicians [85]. Noteworthy, the patients were relatively young (mean age 70 years), with a 
mean CHADS2 score of 2.0 and good prognosis; and without anemia, hemorrhagic 
tendencies, alcohol abuse etc. This differs from many of the aspirin treated patients in routine 
health care who often are much older, frequently with absolute or relative contraindications, 
and an overall poor prognosis [28]. 
Questions have been raised regarding the outcomes with NOACs in unselected and 
potentially different patients in routine care where follow-up is sparse, while warfarin 
treatment implies regular PT-INR controls and tighter contacts with health care personnel. 
There has also been an interest in comparing NOACs with warfarin in countries with high 
quality of treatment, like Western Europe.  
Some early observational outcome studies were conducted in Europe and the U.S.A. in 
different health care settings regarding the use of dabigatran or rivaroxaban in routine care. 
Almost all results have been consistent with the pre-registration clinical trials and did not 
raise any important safety concerns [44,45,86-93]. However, one study showed that warfarin 
treated patients with earlier TIA/ischemic stroke who switched to dabigatran had higher rates 
of ischemic stroke [94]. Dabigatran and rivaroxaban has in some studies been associated with 
a lower risk for ischemic stroke than warfarin [86,90]. Intracranial bleeding has been less 
frequent with dabigatran than with warfarin [86,90,91,93]. GI bleeding has been similar 
[88,93]; or more common with dabigatran [86,90-92], especially in subgroup analyses of the 
elderly [86,88]. Two studies found the overall bleeding rate to be higher with dabigatran than 
with warfarin [91,92], but other studies found similar [44,87,90] rates.  Rivaroxaban has been 
associated with a similar bleeding rate as warfarin [44,87].  
More recently two large observational outcome studies in Europe and the U.S.A  have 
compared dabigatran, rivaroxaban and apixaban to warfarin treatment in routine care and 
found that they seem to be both safe and effective alternatives to warfarin [95,96]. Both 
studies used propensity score matching. NOAC patients with reduced doses were excluded in 
the Danish study of patients in hospital associated care [95], while dose reduction was 
included in the propensity score matching in the study of patients in a U.S. insurance claims 
database [96]. Thus, data on the consequences of dose reductions in elderly and frail NOAC 
treated patients with the largest risks of stroke were limited.  
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Direct inhibition: 
Apixaban 
Rivaroxaban 
 
Direct inhibition: 
Dabigatran 
 
Warfarin decreases the synthesis of vitamin-
K dependent coagulation factors prothrombin 
II, VII, IX, X, as well as protein C and S. 
 
Another large study evaluated only bleeding risks with each NOAC compared to warfarin 
and found lower risks with dabigatran and apixaban, but not with rivaroxaban. The results 
were similar regardless of whether the NOAC patients received standard or reduced doses 
[97].     
Studies comparing the NOACs are also being performed. An observational head-to-head 
study showed that treatment with rivaroxaban 20 mg once daily was associated with 
statistically significant increases in intracranial hemorrhage and major extracranial bleeding, 
including major gastrointestinal bleeding, compared to dabigatran 150 mg twice daily [98]. 
Pharmacology 
Dabigatran is a directly acting thrombin inhibitor while rivaroxaban and apixaban are 
directly acting factor Xa inhibitors [99] (Figure 2, Table 5). All three NOACs might require 
dose reduction in patients with renal insufficency, and they have not been documented in 
patients with eGFR < 25-30 ml/min [37-39,80,82,83]. Dabigatran is to 80% dependent on 
renal elimination. Rivaroxaban and apixaban are less dependent on renal elimination (on 
average 35% and 27%, respectively), but more dependent on hepatic/biliary function [100]. 
The average half-lives are 12-17 hours for dabigatran, 5-9 hours (-13 hours in the elderly) 
with rivaroxaban, and 9-14 hours with apixaban [100]. The half-lives are longer in patients 
with decreased renal function, especially with dabigatran treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Oral anticoagulants and the coagulation cascade [101] 
Prothrombin II Thrombin IIa 
Factor X Factor Xa Factor X 
TF/Factor VIIa 
Factor IVa Factor IV 
Fibrinogen Fibrin (clot) 
Factor VIIIa 
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Another factor of importance is the bioavailability where dabigatran has very low 
bioavailability (3-7%), rivaroxaban almost total bioavailability with food (but only 66% 
without food), and apixaban has a bioavailability of ≈50% (not dependent on food) 
[80,82,83,99]. Low bioavailability might lead to considerable inter- and intraindividual 
variability in plasma concentrations, which is the case for dabigatran [102]. 
Drug-drug interactions by means of the transport protein P-gp are present for all NOACs, 
while the factor Xa inhibitors also interact through the CYP3A4 enzyme. Clinically important 
interactions exist or can be expected with antiarrhythmic agents such as dronedarone and 
amiodarone, or the non-selective calcium antagonists verapamil or diltiazem. HIV treatments 
and oral antifungal drugs also present clinically important interactions, if not as common, 
with the factor Xa inhibitors [80,82,83,100]. 
The variability is important with dabigatran. The plasma concentration varies 10 to 20-fold 
between individuals who are dosed according to recommendations [102, 103]; and the plasma 
concentration has been shown to relate to rates of stroke and bleeding in the RE-LY study 
[102]. The interindividual variability is moderate with rivaroxaban (30-40%) [82]. Apixaban 
has the lowest variability (20 %  intraindividually, 30 % interindividually) [83]. 
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 Dabigatran  Apixaban Rivaroxaban 
Pharmacodynamics    
Mechanism of action Direct thrombin inhibitor Activated factor  
Xa inhibitor 
Activated factor  
Xa inhibitor 
Antidote Idarucizumab No No 
Reversal of effect Idarucizumab 
Hemodialysis 
Prothrombin complex 
concentrate (PCC) possible 
Prothrombin complex 
concentrate (PCC) possible 
Pharmacokinetics    
Bioavailability 3-7% (mean 6,5%) 50% (mean) 66% fasting 
100% with food 
Time to maximum 
concentration 
2 h 1-4 h 2-4 h 
Half-life 12-17 h; important 
prolongation in renal 
insufficiency 
9-14 h; prolongation in 
renal insufficiency 
5-9 h (-13 h in elderly); 
prolongation in renal 
insufficiency 
Elimination Renal (80 %). 1/4 renal. 
3/4 non- renal  
1/3 renal  
2/3 hepatic  
Standard dose 
(atrial fibrillation) 
150 mg BID 
 
5 mg BID 
 
20 mg OD 
 
Dose reduction 110 mg BID, if age ≥ 80 
years or verapamil; consider 
when eGFR 30-49 mL/min, 
weight <50 kg, high risk of 
bleeding 
2,5 mg BID if two of the 
following: S-krea ≥133 
µmol/L,  age ≥ 80, weight ≤ 
60 kg. 
15 mg OD if eGFR 30-49 
mL/min*. 
Plasma concentration-
effect data  
Yes No No 
Trough plasma 
concentrations 
Mean: 91 ng/mL 
25-75 percentile: 61-143 
ng/mL 
High bleeding risk > 200 
ng/mL 
Not available Mean: 32 ng/mL 
5-95 perc.: 6-239 ng/mL 
High bleeding risk > 200 
ng/mL 
Interactions P-glycoprotein inhibitors (P-
gp): 
amiodarone/dronedarone, 
verapamil/diltiazem. 
CYP3A4 or P-gp inhibitors 
increase and inducers 
decrease plasma 
concentrations  
CYP3A4 or P-gp inhibitors 
increase and inducers 
decrease plasma 
concentrations 
Coagulation analyses Hemoclot TI  Anti-FXa.  Anti-FXa.  
Prothrombin complex concentrate (PCC), twice daily (BID), once daily (OD), Estimated glomerular filtration 
rate (eGFR), P-glycoprotein inhibitors (P-gp) 
Table 5 – Pharmacological properties of the NOACs [99,100] 
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Monitoring of NOACs 
Monitoring of NOACs with plasma concentration measurements is not needed in routine 
care. However, direct (drug measurements) and indirect (derived from coagulation tests) 
plasma concentration measurements have been developed for evaluation of drug exposure in 
acute situations and/or before surgical procedures [103-105]; or to provide information for 
dose adjustments in special cases.   
Normal to high concentrations of dabigatran can be determined indirectly with Hemoclot 
TI, while low concentrations demand direct drug analysis by LC-MS/MS [105]. For 
rivaroxaban and apixaban special anti-Xa tests have been developed [100] and drug analysis 
with LC-MS/MS is also available. Plasma concentration-effect relationships have been 
documented for dabigatran [102], but not for rivaroxaban or apixaban. 
1.2.3 Low-dose aspirin 
There is solid documentation of poor efficacy with aspirin for stroke prevention in AF [69]. 
A meta-analysis has indicated only approximately 20 % relative risk reduction compared to 
placebo [68]. Compared to aspirin, warfarin [68,75] or apixaban [85] provide substantially 
better protection against stroke without substantial increases in bleeding. Guidelines have 
since the comparative randomized trials in the 1990s recommended OAC over aspirin 
treatment [68], and recent guidelines have emphasized the importance of OAC treatment 
[52,53]. Still, aspirin has been widely used, even after the introduction of NOACs [35, 69]. 
Complicating co-morbidities such as cancer, dementia, anemia, alcohol abuse, renal disease, 
earlier severe bleeding and frequent falls has been shown to be more frequent in aspirin 
treated patients [28]. This suggests that physicians often might be reluctant to initiate OAC 
treatment in frail patients [28,69].  It should be mentioned  that aspirin is still a valid 
treatment for ischemic heart disease [106], which is a common co-morbidity in AF-patients 
[42]. 
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2 AIMS 
2.1 GENERAL AIM 
The general aim of this thesis was to increase knowledge on the use and outcomes with 
available antithrombotic treatments in AF patients in routine care in the Stockholm health 
care region before and after the introduction of NOACs. 
2.2 SPECIFIC AIMS 
 To describe the AF population in the Stockholm health care system: demographics, 
co-morbidity, risk stratification, antithrombotic treatment; and to investigate which 
implications data from primary care may have for analyses of the CHADS2 and 
CHA2DS2VASc risk scores. 
 To evaluate and discuss the outcomes of patients with non-valvular AF receiving 
treatment with warfarin, aspirin or neither related to different CHA2DS2VASc-scores, 
age and complicating co-morbidities prior to the introduction of NOACs. 
 To describe OAC treatment in patients with non-valvular AF in the Stockholm health 
care region before and after the introduction of NOACs. 
 To compare the persistence with all OACs in patients with AF and a definite 
indication for OAC treatment (CHA2DS2VASc score 2-9); and to compare adherence 
to treatment with NOACs, evaluate the use of aspirin, and investigate patient 
characteristics associated with poor persistence. 
 To compare outcomes regarding both effectiveness and safety with NOAC versus 
warfarin treatment in OAC-naïve patients with non-valvular AF in routine care, with 
special considerations regarding old and frail patients; and to explore the effects of 
dose reductions when prescribing NOACs. 
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3 MATERIAL AND METHODS 
3.1 SETTING 
The studies included in this thesis were all conducted in Sweden where healthcare is 
publically financed and accessible to all residents. Since the second half of the 20th century 
national health registers were developed. These registers have mandatory reporting for 
healthcare providers and are managed by the National Board of Health and Welfare. The 
unique personal identification number can be used to merge data from various registers and 
from medical records so that study subjects can be followed in the health care systems over 
time. The coverage is almost complete. These registers have provided data for numerous 
epidemiological studies and are considered to be of high quality [107-109]. 
3.2 PERSONAL IDENTIFICATION NUMBER 
The personal identification number is a unique identifier which is used in all public 
administration in Sweden for all citizens and immigrants who become permanent residents or 
intend to stay in Sweden for at least one year. It consists of the birth date and an identification 
number. Thus, information from all administrative and many other registers can be linked to 
an individual. When conducting research, the data is generally anonymised or pseudonymised 
(the encryption key is kept with a third party to allow for additional record linkage).   
3.3 DATA SOURCES 
The data sources for the individual studies consist of four research databases based on 
record linkage of health care registry data.  
3.3.1 National Patient Register (NPR) 
The National Patient Register (NPR) is managed by the National Board of Health and 
Welfare and consists of codes for diagnoses and procedures on a national level. The NPR is 
well validated [108] and includes hospital discharges since 1964. The register also covers 
outpatient visits to both private and public caregivers from 2001. Diagnoses and procedures 
in primary care are, however, not covered in the NPR.  
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3.3.2 Causes of Death Register  
The Causes of Death Register (The National Board of Health and Welfare) contains 
information on all deaths since 1961. The register covers all Swedish residents, regardless of 
citizenship or of whether the death occurred in Sweden or abroad [110].  
3.3.3 Prescribed Drug Register  
The Prescribed Drug Register (The National Board of Health and Welfare) contains 
complete data on all prescription drugs dispensed in Sweden from July 2005: amounts, 
dosages, expenditures, reimbursement, age and gender of the patient regardless of 
reimbursement status, co-payment and prescriber category [109]. The information has a high 
validity as almost 100% of the prescriptions are recorded together with a unique personal 
identification number. 
3.3.4 VAL 
The administrative health data register of the Stockholm health care region 
(Vårdanalysdatabasen, VAL) was used in all four studies. VAL contains pseudonymized data 
regarding diagnoses, age, sex, prescription claims, hospitalizations and other healthcare 
consultations, migration and death for all individuals in the Stockholm health care region.  
Diagnoses from primary care are available since 2003, and for secondary care (outpatient 
visits and hospitalization) since 1993. The data for secondary care in VAL is the same as that 
found in the National Patient Register for the Stockholm region, and therefore well validated 
for use in epidemiological studies [107-108]. VAL also contains individual-level data on all 
prescription drugs dispensed anywhere in Sweden to inhabitants in the region since July 
2010: amounts, expenditures and reimbursement, the age and gender of the patient, co-
payments and prescriber category. This information is derived from the national Prescribed 
Drug Register [109]. 
In Studies I and II data from VAL were linked with data from the NPR [107-108] to cover 
other parts of Sweden, the Prescribed Drug Register [109], and the Causes of Death Register 
[110]. The reason for this record linkage was mainly that VAL did not include prescribed 
drugs before 2010. In study III-IV VAL was used without additional record linkage. 
3.4 STUDY POPULATIONS 
Studies I-II included all patients with non-valvular AF recorded in inpatient care, specialist 
ambulatory care or primary care in the Stockholm health care region. In study I 43 353 
patients with a diagnosis of non-valvular AF during 2006-2010 were included. Study II 
included 41 810 patients with a diagnosis of non-valvular AF recorded during 2005-2009 and 
outcomes were assessed in 2010.  
Studies III-IV included individuals in the Stockholm health care region having initiated 
antithrombotic treatment and with a diagnosis of non-valvular AF prior to initiation. Study III 
included all first claims of either warfarin (n=9969), dabigatran (n=2701), rivaroxaban 
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(n=2074), apixaban (n=1352), or aspirin (n=4540) from April 2011 until December 2014, in 
individuals with CHA2DS2VASc-scores of 2-9. During this period there were no specific 
regional recommendations regarding choice of NOACs. Study IV was restricted to OAC 
naïve patients who initiated treatment with a NOAC (n=9292) or warfarin (n=12938) from 
January 2012 until December 2015. 
3.5 METHODS 
This thesis consists of four population based studies of patients with non-valvular AF. 
 Study I was a cross-sectional study. The prevalence of AF in different levels of health care 
and the importance of diagnoses from primary health care in the assessment of 
CHA2DS2VASc-scores were investigated; as well as the demographic characteristics of AF 
patients and their antithrombotic treatment at different CHA2DS2VASc-scores.   
Study II was a cohort study describing the risks of ischemic stroke, serious bleeds, or death 
with warfarin, aspirin, or no antithrombotic treatment during 2010. The risks were stratified 
by CHA2DS2VASc-scores, age and complicating co-morbidities. 
Study III was a cohort study comparing the persistence and adherence to different OAC 
treatments and low-dose aspirin. Prescription claims were analyzed both crudely and in 
multivariate analysis adjusting for age, sex, prescriber category, prior OAC treatment, and 
number of drugs claimed by the patients.  
Finally, study IV was a cohort study comparing the effectiveness and safety of NOAC and 
warfarin treatment. Cox regression analyses were performed evaluating TIA/ischemic or 
unspecified stroke/death (adjusted for individual CHA2DS2VASc criteria with age as a 
continuous variable), and severe bleeds (adjusted for sex and adapted HAS-BLED criteria 
with age as a continuous variable); and for components of the composite co-primary 
endpoints. Subgroup analyses were performed focusing on patients 80 years and above, and 
patients with a prior severe bleed. Exploratory analyses of dose reductions of NOACs were 
conducted and dabigatran, rivaroxaban and apixaban were compared individually with 
warfarin treatment. 
3.6 STATISTICAL METHODS 
In all four studies descriptive statistics were used and data were presented as proportions or 
mean values with 95% confidence intervals (CI), as appropriate. In study II two-sample tests 
of proportions for relative frequencies were also performed.  
In study III multivariate logistic regression was employed to evaluate persistence in 10 444 
OAC initiations (9 710 individual patients) at one year. Adjustments were made for age, sex, 
prior OAC treatment, prescription from primary care, and the total numbers of drugs claimed 
by the patients. Persistence was defined as the proportions of patients on each drug who 
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claimed the treatment in question during 6 month intervals, excluding those who died during 
the interval. Complementary analyses were performed for OAC naïve patients and also with 
the inclusion of patients who died during follow-up in the definition of persistence. In order 
to confirm the model individual patients on first and second line OAC treatment were 
compared separately. Sensitivity analyses were performed, comparing persistence with 3, 4 or 
6 month intervals in the assessment of prescription claims. Different definitions of adherence 
were compared using two-sample tests of proportions for relative frequencies.  
In study IV Cox regression analyses were conducted for crude and adjusted estimates 
evaluating two co-primary endpoints: the composite endpoint TIA/ischemic or unspecified 
stroke/death (adjusted for individual CHA2DS2VASc criteria and age as a continuous 
variable), and severe bleeds (adjusted for sex and adapted HAS-BLED criteria with age as a 
continuous variable). Secondary analyses were performed for the components of the co-
primary endpoints. Patients were censored at primary endpoints; migration out of the region; 
when claiming a drug from the comparator group(s) or low-dose aspirin; or at the end of 
follow-up (December 31, 2015).  
Alternative analyses were performed of outcomes during the first year of treatment, 
outcomes according to the intention-to-treat principle (no censoring for claims of other OAC 
treatments or low-dose aspirin), fully adjusted outcomes, as well as an analysis of overall 
mortality as a non-competing end-point in order to address the risks of informative censoring 
and/or confounding. Propensity score adjusted analyses yielded essentially the same results. 
To evaluate possibly non-proportional hazards plots of Schoenfeld residuals were analysed 
and Cox regression with covariate-time interactions was performed.  
The statistical analyses were performed using Excel 2007 (Microsoft Corporation, 
Redmond, WA), SAS Enterprise Guide 4.2, or SAS Enterprise Guide 6.1  (SAS Institute Inc., 
Cary, NC). 
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ETHICAL CONSIDERATIONS 
The results in this thesis are based on record linkage from databases with health care 
registry data (see 3.3 - Data sources). All studies were approved by the Regional Ethical 
Review Board in Stockholm (Study I-II: EPN 2010/1158-31/2, Study III-IV: EPN 2015/579-
31/2) 
These databases include diagnoses registered at outpatient health care consultations and 
hospital discharges, as well as claims of prescription drugs at any pharmacy in Sweden.  The 
databases are pseudonymised, which means that the personal identification numbers are 
encrypted with a database encryption key which allows the possibility to update the databases 
with additional information if needed. The encryption key is managed by a third-party key 
manager and the researchers never come in contact with identifiable data. The analyses were 
performed on a local password protected computer. The raw data are transferred to a CD and 
archived after the end of the studies.  
All analyses are presented at the group level and individual prescribers or patients can never 
be identified.  Informed consent was not applicable since the patients are not identified and 
the studies comprised thousands of individuals. However, all studies were approved by the 
Regional Ethical Review Board in Stockholm and a personal data permit has been obtained 
from the Public Healthcare Services Committee, Department of Healthcare development of 
the Stockholm County Council.  
There is a risk of breaching personal integrity when studying data from health care 
registries. However, all analyses were performed on encrypted data and grouped such that no 
data can be derived to any specific patient. 
Some prescribers might experience a breach of integrity if inadequate compliance with 
guidelines is identified. However, no individual prescribers can be identified and no reporting 
of results at a prescriber level has been done. 
The major ethical question regards the practice of not obtaining informed consent from 
patients when conducting large registry based epidemiological studies. Some individuals 
might feel that investigations of their age and sex in relation to their diagnoses and treatments 
constitute an invasion of privacy. This thesis concerns antithrombotic treatment for atrial 
fibrillation which probably is less sensitive than analyses of crime, abuse, psychiatric 
conditions or psychiatric drugs, but the objection might still exist. 
Arguments against obtaining informed consent are that the large amount of patients would 
demand vast resources, which would make it impossible to conduct large academic registry 
based studies. An important argument for registry studies is that population based registries 
include patients that might be difficult to study under other conditions, i.e. patients with 
dementia, addictions, severe illnesses or decreased autonomy; and thus provide excellent 
complements to randomized controlled studies with selected, often homogenous and rather 
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uncomplicated patients. Loss of patients in registry based studies, especially of patients that 
are difficult to include in other studies, would significantly decrease the utility value of these 
studies.  
In order to send letters of informed consent the individuals in the databases would have to 
be identified. It is possible that some individuals would see this identification and letter as a 
larger breach of integrity than to have anonymously been included in a large scientific 
material.      
There is no direct benefit for the individuals included in the four studies of this thesis. 
However, the findings might contribute to better thromboprophylactic treatment for patients 
with AF in the future, whether they were included in the studies or not. 
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4 RESULTS 
4.1 STUDY I 
In Study I we described the AF population in the Stockholm health care region, and 
investigated the importance of diagnoses from primary health care in the assessment of 
CHA2DS2VASc-scores.  
During a 5-year interval (2006-2010) 43 353 patients with a diagnosis of non-valvular AF 
could be found in inpatient care, specialist ambulatory care or primary care, with a grossly 
equal distribution between the levels of care (Figure 3). Of interest, 64% of the entire cohort 
of patients with AF had the diagnosis in primary care, and 12% of the patients had the 
diagnosis only in primary care (Figure 3).  
 
 
Figure 3 - Overlap between inpatient care, primary health care and specialist 
ambulatory care of the prevalences of a diagnosis of non-valvular atrial fibrillation 
during the years 2006–2010 among 43 353 patients who were alive at the end of 2010 in 
the Stockholm health care region. 
 
Warfarin appeared to be underused and aspirin overused. In 2010 warfarin prescriptions 
were claimed by 47.2%, and aspirin by 41.6% of the entire cohort. On the other hand, many 
patients with a doubtful indication received OAC treatment: 34% of patients with a 
CHA2DS2VASc score of 1 and 20% with a CHA2DS2VASc score of 0 had warfarin, despite 
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poor documentation of clinical benefit. Aspirin was more frequently used instead of warfarin 
among women and elderly patients. 
The mean CHA2DS2VASc-score was 3.82 (4.67 for women and 3.14 for men). Registry 
CHA2DS2VASc scores were underestimated without co-morbidity data from primary care 
(Table 6). The mean CHA2DS2VASc-score of patients with a diagnosis only in inpatient care 
or specialist ambulatory care increased from 3.63 to 3.83 when comorbidities registered in 
primary care were added. This underestimation of CHA2DS2VASc-scores might thereby have 
overestimated treatment benefits in low-risk patients in earlier studies. 
 
CHA2DS2VASc 
Excluding 
diagnoses from 
primary care 
 Including  
diagnoses from 
primary care 
 
0 6.95%  (6.70%-7.21%) 6.34% (6.09%-6.58%) 
1 10.51% (10.21%-10.82%) 9.62% (9.32%-9.92%) 
2 13.80% (13.45%-14.14%) 12.49% (12.16%-12.82%) 
3 16.61% (16.24%-16.98%) 15.14% (14.79%-15.50%) 
4 17.58% (17.20%-17.96%) 17.43% (17.06%-17.81%) 
5 14.84% (14.49%-15.20%) 16.09% (15.72%-16.46%) 
6 10.66% (10.35%-10.97%) 11.89% (11.57%-12.22%) 
7 5.94% (5.70%-6.18%) 6.96% (6.71%-7.22%) 
8 2.51% (2.35%-2.66%) 3.25% (3.08%-3.43%) 
9 0.60% (0.52%-0.67%) 0.77% (0.68%-0.85%) 
 
 
 
    
 
Table 6 - CHA2DS2VASc scores in live patients diagnosed with non-valvular atrial 
fibrillation in special ambulatory care and/or inpatient care 2006-2010. The scores 
suggest that patients had no (score = 0), possible (score = 1) or definite (score ≥ 2) 
indications for anticoagulant treatment. Comparison of scores obtained when excluding 
and including diagnoses from primary care. 38 337 unique individuals. Values within 
parentheses are 95% CI. 
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4.2 STUDY II 
In Study II, we investigated the stratified risks for stroke and bleeding with warfarin, low-
dose aspirin or no treatment at different CHA2DS2VASc-scores (Figure 4), and in patients 
with very high age or complicating co-morbidities (Table 7). The observations confirmed 
earlier findings of undertreatment with warfarin. 
 
 
Figure 4 - Risks of suffering ischemic stroke (IS) and intracranial bleeding 
(hemorrhagic stroke + traumatic intracranial bleeding) (IB) during 2010 in 39 875 AF 
patients with warfarin, aspirin or no treatment (clopidogrel excluded). 
 
Half of the high-risk patients (CHA2DS2VASc-scores ≥2 ) treated with aspirin were 
obvious candidates for anticoagulant treatment with no identified contraindications; they had 
a high risk for ischemic stroke (4.0%), a low bleeding risk (1.8%), and a moderate mortality 
rate (8.4%) (Table 7). The other half of the aspirin treated patients had possible or probable 
contraindications and high risks for ischemic stroke (5.2%), bleeding (5.0%) and death 
(19.3%) (Table 7). The issue of undertreatment with anticoagulants is difficult to evaluate in 
such patients, and the risk/benefit is less advantageous compared to uncomplicated patients.  
  35 
 
Outcomes 
during 2010 Warfarin 
Risk ratio 
(complicated/ 
uncomplicated) 
 
Aspirin 
Risk ratio 
(complicated/ 
uncomplicated) 
 
 Uncomplicated Complicated Uncomplicated Complicated 
n 10024 4189   6551 6173   
Ischemic 
stroke 2.0(1.7-2.3)% 2.1(1.6-2.5)% 1.0 (0.8-1.3) 4.0(3.5-4.4)% 5.2(4.6-5.8)% 1.3 (1.1-1.5) 
Thrombo-
embolism 3.0(2.6-3.3)% 3.1(2.6-3.6)% 1.0 (0.8-1.3) 5.5(5.0-6.1)% 6.8(6.1-7.4)% 1.2 (1.1-1.4) 
Hemorrhagic 
stroke 0.5(0.4-0.6)% 0.9(0.6-1.2)% 1.8 (1.2-2.8) 0.4(0.2-0.5)% 1.0(0.8-1.3)% 2.7  (1.7-4.2) 
Traumatic 
intracranial 
bleeding 0.3(0.2-0.4)% 0.6(0.3-0.8)% 1.8 (1.1-3.0) 0.2(0.1-0.3)% 0.7(0.5-0.9)% 3.4 (1.8-6.4) 
Any severe 
bleeding 1.9(1.6-2.2)% 3.8(3.2-4.4)% 2.0 (1.6-2.4) 1.8(1.5-2.2)% 5.0(4.5-5.6)% 2.7 (2.2-3.4) 
Deceased (all 
cause) 2.9(2.6-3.3)% 6.2(5.5-6.9)% 2.1 (1.8-2.5) 8.4(7.8-9.1)% 
19.3(18.3-
20.3)% 2.3 (2.0-2.5) 
Table 7 – Outcomes among 26 937 atrial fibrillation patients with CHA2DS2VASc-
scores 2-9 in the Stockholm health care region with and without potential 
contraindications (dementia, alcohol abuse, renal disease, anemia, earlier severe 
bleeding, or frequent falls), respectively. Values within parentheses are 95% CI. 
 
One-year risks for ischemic stroke were low in patients with low CHA2DS2VASc-scores: 
1.0-1.2% with aspirin, 0-0.3% with warfarin, and 0.1-0.2 % without treatment at 
CHA2DS2VASc-scores 0-1. These low risks should be considered when discussing more 
aggressive use of OAC treatment. The higher stroke rate in the aspirin treated group reflects 
the imbalance between groups regarding unmeasurable baseline covariates, and comparisons 
between the groups should not be made (see 6.1 - Methodological considerations). 
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4.3 ANTICOAGULANT TREATMENT OF ATRIAL FIBRILLATION BEFORE AND 
AFTER THE INTRODUCTION OF NOACS IN THE STOCKHOLM HEALTH 
CARE REGION 
After the publication of the European Guidelines for AF in 2010 and the introduction of 
NOACs, which commenced in late 2011, the initiations with NOACs have increased steadily 
while warfarin has decreased [18]. The choice between the three NOACs was fairly equal up 
until January 2015 when apixaban was recommended as an alternative to warfarin in the 
regional recommendations, with dabigatran as an secondary alternative for selected patients. 
From November 2015, AF patients were more likely to receive apixaban than any other 
OAC, while less than 20% of the initiations were with warfarin. [18]. From January 2016 
apixaban is recommended as the OAC of choice for AF-patients in the Stockholm region, 
with warfarin and dabigatran being recommended as secondary alternatives. 
Figure 5 summarizes changes in the AF population and the treatment patterns before and 
after the introduction of NOACs, i.e., in 2011 and 2015. The number of living resident 
patients with non-valvular AF in VAL during a 5-year identification period has increased 
from 41702 to 47698 (patients having moved into the region during the 5-year period were 
excluded in order to improve risk stratification). The proportion of patients treated with OAC 
increased from 50.8% in 2011 to 70.3% in 2015. Among patients with a definite indication 
for anticoagulant treatment (CHA2DS2VASc 2-9) 75% were treated with an OAC in 2015 
compared to 54% in 2011. The largest increases of OAC treatment were found among 
patients with complicating co-morbidities and in patients aged 80 years and above.  In 
absolute numbers there were more AF patients treated with warfarin after the introduction of 
NOACs than before (over 20 000), but the proportion had decreased slightly to 46.3% while 
24.0% had claimed a NOAC in 2015. 
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Figure 5 – Anticoagulant treatment of non-valvular AF in the Stockholm health care 
region. Numbers of patients with warfarin, NOAC and no OAC treatment 2011 and 
2015 in different age groups  
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4.4 STUDY III 
In Study III, persistence with the different NOACs during 2011-2014 was compared to the 
persistence with warfarin treatment in patients with non-valvular AF and CHA2DS2VASc 
scores 2-9. Also persistence with, and switches from low-dose aspirin were analyzed. 
The persistence with any OAC, including switches, was high: 88.2% (CI 87.5%-88.9%) at 
one year and 82.9% (CI 81.8%-83.9%) at two years (Figure 6). The crude persistence was 
85.0% (CI 84.2%-85.9%) with warfarin, 85.9 % (CI 81.8%-90.1%) with apixaban, 74.4% (CI 
72.3%-76.5%) with dabigatran, and 77.4% (CI 74.6%-80.2%) with rivaroxaban after one year 
the (Figure 6).  
 
 
 
 
Figure 6 – Unadjusted persistence with anticoagulant treatment in non-valvular atrial 
fibrillation patients with CHA2DS2VASc scores 2-9. The analysis comprises 16 096 OAC 
initiations in 14 426 individual patients. 
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Multivariate analysis of the persistence at 1 year confirmed statistically significant 
differences, with initiations on warfarin and apixaban having higher odds for persistence than 
initiations on dabigatran or rivaroxaban (Table 8). Factors significantly associated with lower 
persistence were female sex and number of drugs, while initiation of treatment from primary 
care was associated with a higher persistence (Table 8). 
 
 
Treatment persistence 
 
Odds Ratio 
Estimate 95% CI P-value 
Warfarin vs apixaban 0.88 0.62-1.25 0.47 
Warfarin vs dabigatran 1.81 1.57-2.10 <.0001 
Warfarin vs rivaroxaban 1.50 1.24-1.81 <.0001 
Apixaban vs dabigatran 2.07 1.45-2.94 <.0001 
Apixaban vs rivaroxaban 1.71 1.18-2.47 0.004 
Rivaroxaban vs dabigatran 1.21 1.00-1.46 0.053 
Female sex 0.86 0.78-0.96 0.006 
Age (per year) 1.00 0.99-1.00 0.12 
Prior OAC treatment 0.97 0.82-1.14 0.68 
Prescription in Primary Care 1.21 1.08-1.35 0.001 
Number of Drugs (per drug) 0.95 0.93-0.97 <.0001 
Table 8 – Odds ratio estimates of treatment persistence at 12 months in patients  with 
non-valvular atrial fibrillation and CHA2DS2VASc scores 2-9 who were initiated with 
warfarin (n=7 452), dabigatran (n=1 778), rivaroxaban (n=925), or apixaban (n=289). 
The analysis comprises 10 444 OAC initiations in 9 710 individual patients. 
 
The adherence (proportion of days covered >80%) was above 90% for all NOACs; 
significantly higher with rivaroxaban compared to dabigatran (p<0.001), but not compared to 
apixaban (p=0.14).Full adherence (≥ 100 % of days covered by dispensed drug) was 
significantly more common with rivaroxaban (79.7%) than with apixaban (71.4%), and 
dabigatran (72.7%). 
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4.5 STUDY IV 
In study IV we compared the efficacy and safety of NOAC and warfarin treatment in OAC-
naïve patients with non-valvular AF. NOAC treated patients were younger (72.9 vs. 74.1 
years) and had lower CHA2DS2VASc-scores (3.42 vs. 3.68) than warfarin treated patients.  
NOAC vs. warfarin treatment was associated with similar risks for TIA/Ischemic or 
unspecified stroke/death (HR 0.93; 0.84-1.03) and severe bleeds (HR 1.04; 0.88-1.22) (Table 
9). In secondary analyses NOAC treatment was associated with lower risks of intracranial 
bleeds (HR 0.72; 0.51-1.00) or hemorrhagic stroke (HR 0.50; 0.28-0.87), but a higher risk for 
gastrointestinal bleeds (HR 1.24; 1.00-1.52). 
 
Endpoint   
NOAC vs. warfarin 
 
 
 
   
Crude HR  
(CI 95) 
 
Adjusted HR  
(CI 95) 
Intention-to-
treat 
Adjusted HR  
(CI 95) 
 
Fully 
adjusted  
HR (CI 95) 
(CHA2DS2VASc 
2-9) 
Adjusted HR 
(CI 95) 
TIA/Ischemic 
stroke/stroke 
unspecified/death 
0.82* (0.73-0.91) 0.93 (0.84-1.03)1 0.91* (0.83-0.99)
1 0.91 (0.82-1.01)3 0.96 (0.86-1.07)1 
TIA/Ischemic 
stroke/stroke 
unspecified
 
0.86 (0.72-1.03) 0.93 (0.78-1.12)1 0.96 (0.82-1.13)
1 0.92 (1.03-1.05)3 0.98 (0.81-1.18)1 
Ischemic stroke 0.76* (0.60-0.96) 0.83 (0.66-1.06)1 0.91 (0.74-1.12)
1 0.81 (0.64-1.03)3 0.84 (0.66-1.08)1 
Death 0.79* (0.70-0.90) 0.93 (0.81-1.05 1 0.88* (0.79-0.98)
1 0.91 (0.80-1.03)3 0.95 (0.83-1.08)1 
Any severe bleed 0.99 (0.84-1.16) 1.04 (0.88-1.22)2 0.95 (0.82-1.10)
2 1.05 (0.89-1.24)3 1.06 (0.89-1.25)2 
Intracranial bleed 0.65* (0.47-0.91) 0.72* (0.51-1.00)2 0.63* (0.46-0.85)
2 0.69* (0.50-0.97)3 0.76 (0.54-1.06)2 
Hemorrhagic 
stroke 
0.45* (0.26-0.80) 0.50* (0.28-0.87)2 0.48* (0.29-0.80)
2 0.49*(0.28-0.86)3 0.48* (0.27-0.86 2 
Other 
intracranial bleed 
0.82 (0.54-1.23) 0.90 (0.59-1.36)2 0.74 (0.51-1.10)
2 0.86 (0.56-1.30)3 1.01 (0.66-1.54)2 
Gastrointestinal 
bleed 
1.21 (0.98-1.48) 1.24* (1.00-1.52)2 1.12 (0.93-1.35)2 1.28* (1.03-1.58)3 1.28* (1.03-1.59)2 
Table 9–Hazard ratios (HR) of study outcomes in 22 230 OAC-naïve patients with 
non-valvular AF initiated on anticoagulant treatment; NOAC vs. warfarin. 
Significant differences compared to warfarin are denoted *. 
1 Adjusted for individual CHA2DS2VASc criteria and age as a continuous variable 
2 Adjusted for age, sex and prior severe bleeds 
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After adjustments there were no significant differences between NOAC and warfarin 
treatment in high risk patients aged 80 and above for TIA/Ischemic or unspecified 
stroke/death (HR 0.99; CI 95 0.86-1.14) or any severe bleed (HR 1.14; CI 95 0.89-1.47). The 
risks were also similar between treatments in patients with a prior severe bleed: TIA/Ischemic 
or unspecified stroke/death (HR 1.00 ; CI 95 0.75-1.34), new severe bleed (HR 1.11; CI 95 
0.75-1.64). 
Explorative analyses of the influence of dosages on outcomes suggested that standard dose 
NOAC treatment was associated with fewer deaths and similar risks of severe bleeding 
compared to warfarin treatment in patients < 80 years, but there were increased risks of dying 
or suffering a gastrointestinal bleed among dose reduced younger patients. In patients aged 80 
and above dose reduction of NOAC treatment was associated with a marked risk reduction 
for hemorrhagic stroke without any increase in gastrointestinal bleeds compared to warfarin 
treatment. 
There were no significant differences between rivaroxaban or apixaban and warfarin 
treatment in exploratory analyses. Dabigatran treatment was associated with lower risks of 
suffering death and intracranial bleeds, but a higher risk for gastrointestinal bleeding 
compared to warfarin. There were no trends suggesting that warfarin treatment would have 
better effectiveness or safety than any of the individual NOACs. 
In summary this population based cohort study of routine care indicated similar or better 
effectiveness and safety with NOAC compared to warfarin treatment. NOACs were 
associated with fewer intracranial bleeds, but more gastrointestinal bleeds. 
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5 DISCUSSION 
5.1 METHODOLOGICAL CONSIDERATIONS 
5.1.1 Study design and generalizability 
Registry based observational studies provide the possibility to investigate the introduction of 
new drugs in representative populations and from different angles compared to randomized 
trials. Also, the appropriateness of prescriptions in routine care can be investigated. 
Independent comparative effectiveness studies provide additional validation of the benefit 
and risks of new drugs in routine care [15]. Treatment results can also be assessed in ways 
that differ from those commonly used in the randomized trials. 
The studies in this thesis all had a non-excluding design. Studies I and II were descriptive 
with the aim of characterizing the AF population, treatment and outcomes prior to the 
introduction of NOACs. Studies III and IV were cohort studies comparing persistence, 
effectiveness and safety between treatments.  
The studies comprised all eligible patients recorded in the administrative health care database 
(VAL) of the Stockholm County Council, which includes diagnoses from inpatient care, 
specialist ambulatory care, and primary care. VAL also contains individual level data on all 
prescription drugs dispensed anywhere in Sweden to inhabitants in the region. Such rather 
complete coverage increases the external validity and the generalizability of the findings.  
But organization of health care, regional drug and therapeutic recommendations, and 
socioeconomic factors might limit the generalizability of studies based on regional data 
collection. Studies I and II investigated treatment and outcomes prior to the introduction of 
NOACs and might not be relevant in the post-NOAC era. Study III investigated persistence 
with warfarin and NOACs in a setting where warfarin was recommended as first line 
treatment in AF according to regional guidelines. The regional recommendations have 
changed since then and recommendations may differ in other health care settings. Study IV 
only included new initiators of OAC treatment. The results including switches between drugs 
were assessed in intention-to-treat analyses, but have not been closer evaluated. The 
outcomes of the large number of AF patients switching from warfarin to NOAC treatment 
were not evaluated. This should be considered when interpreting the results. 
5.1.2 Using health care registers in epidemiological research 
There are several advantages of using administrative health care registers such as VAL 
when evaluating the effectiveness of drug therapies [20,107]. The data is already structured 
and covers large parts of or, preferably, the entire health care system over a long period of 
time. These registers are often representative of routine clinical care and include all patients, 
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not only those eligible for a clinical trial, or those treated at selected health care units 
participating in observational registers. The data are prospectively recorded for all patients 
[20,107].  
However, there are also limitations. A record is generated only at encounters with the health 
care system or a claim of prescription drugs. Diagnoses are only considered when registered 
as ICD-10 codes and reported into the administrative register. The diagnoses might be 
inaccurate, and information might be missing. ICD-10 codes might be repeated at follow-up 
visits or transfers between clinics which complicates the assessment of new events. Death is 
an accurate end-point in the registers, but causes of death are not which might lead to 
underestimations of other outcomes. Systematic lack of information might lead to 
misclassification and more residual confounding [20]. One example is lack of registered 
diagnoses in untreated patients who might have sparse contact with health care due to 
mistrust, psychiatric conditions, alcoholism, or other reasons. This systematic lack of 
information might lead to false classification of these individual as low-risk and differential 
misclassification when comparing with active treatment. 
5.1.3 Validity of diagnoses, and treatments  
The coverage of healthcare records in the VAL database is almost complete, with almost 
100% of discharges and consultations having at least one registered ICD-10 diagnosis, but 
some visits and diagnoses from private care and nursing homes might be missing. The 
validity of hospital diagnoses in Sweden is well documented [107,108,111], but diagnoses in 
primary care records are less validated [35,46,47]. In the CHA2DS2VASc-score only heart 
failure with an ejection fraction below 40% is a proven risk factor for stroke, but the ejection 
fraction cannot be identified in health care registers [52]. The information regarding 
prescription claims is accurate [109], but we do not know if patients actually took their 
prescribed and claimed treatments. 
5.1.4 Validity of outcomes 
In study II we included patients based on a recorded diagnosis of AF during a five year time 
span but used the same index date for follow-up. The outcomes were then assessed during the 
relatively short time span of one year, in order to avoid misclassification. By including 
patients diagnosed during a large time span and then commencing follow-up at a common 
point in time (unrelated to the occurrence of a diagnostic code or a prescription claim) we 
reduce selective misclassification due to the associations of ICD-10 codes of AF, treatment 
and ICD-10 codes for outcomes (particularly for stroke). The method used in study II thus 
leads to reduced bias when evaluating outcomes of treatment for the entire AF population.   
In study III we wanted to evaluate true discontinuation of antithrombotic treatments and 
therefore used prescription claims with a generous time-window as the primary outcome. 
Several papers about adherence and/or persistence with NOACs treatment in AF patients 
have been published, but both the settings, the definitions of adherence and/or persistence and 
the results are highly variable [112]. Prescription claims are reliable and valid measures of 
continued treatment, but sensitive to definitions such as time window and other 
methodological definitions. Prescription claims are often irregular and patients on treatment 
might wrongly be classified as discontinued if the time-windows are too short [113], but the 
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sensitivity might differ from one country to another [112]. It is especially important to avoid 
selective misclassification when evaluating warfarin treatment where one claim lasts 6 
months for many patients in Sweden, in comparison to other treatments where the claim 
usually lasts only 3 months. The availability of new treatments might in some settings have 
driven switches from warfarin to NOACs due to financial or practical reasons unrelated to 
tolerability. In study III we made efforts to avoid bias due to short time windows when 
assessing prescription claims, variable follow-up time, mortality, changes in regional 
guidelines, or temporary indications among patients with CHA2DS2VASc scores 0-1. 
In study IV the outcomes were carefully defined to avoid counting events registered during 
follow-up visits or transfers between inpatient clinics as new outcomes. Patients were 
included at an index date, i.e. the initiation of OAC treatment, and we found signs of 
misclassification due to transfer between clinics or follow-up visits after TIA/ischemic stroke. 
We therefore included TIA, ischemic and unspecified stroke only if they occurred as the main 
or first secondary diagnosis in inpatient hospital based acute somatic care [54]. Severe bleeds 
were included when occurring in hospital based acute somatic care as main or secondary 
diagnoses, and hospitalized bleeds were analyzed as a secondary endpoint [114].With these 
conservative definitions the absolute risks for stroke and bleeding with OAC treatment might 
be slightly underestimated, but the accuracy is improved.   
5.1.5 Confounding by indication 
Confounding by the indication for therapy is the major limitation of observational 
comparative effectiveness studies [15]. This is due to the fact that the prescription of drugs by 
physicians is influenced by many factors. Drugs are often systematically channeled to certain 
types of patients, based on their indications and contraindications. Residual confounding is 
the inability to compensate for differences in patient characteristics between treatment groups 
when comparing outcomes. There are always unmeasured factors such as biological age 
(fitness), severity of the co-morbidities, and lifestyle factors influencing the outcomes. If 
these factors differ systematically between the compared groups they might mislead the 
researcher into drawing the wrong conclusions. Thus, observational studies should not be 
used to draw conclusions about causal effects and efficacy, only to assess and discuss the 
effectiveness in routine care and indicate possible causal effects. The main aims of 
observational comparative effectiveness studies are to confirm results from randomized trials 
or to seek evidence when results from randomized trials are lacking. Unexpected differences 
between treatment groups should be interpreted as indications warranting either confirmation 
in randomized trials or support by consistent findings in other observational trials from other 
populations and settings.  
Unmeasurable baseline factors might affect both the choice of treatment and the outcomes, 
leading to confounding by indication. But unexpected differences in outcomes between 
treatment groups might also be due to different utilization of the treatments in the studied 
populations, or different management of the treatments in health care, compared to the 
randomized trials [15]. Routine care patients are often older and have more co-morbidities 
than trial patients. They might also be less motivated and their follow-up is usually less 
thorough leading to higher discontinuation and lower adherence which may also differ 
between treatments. Run-in periods in clinical trials might lead to underestimation of side-
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effects which are of importance when using drugs in a routine setting. Finding and exploring 
these differences are other reasons to conduct observational comparative effectiveness 
studies. Results from observational studies can be used to fine tune recommendations and 
improve the use of drugs in routine care. 
There are several methods that can be used to reduce, if not completely suppress, 
confounding by indication [15]. The analysis can be restricted to certain types of patients, for 
example only new users, only patients with standard dose, patients without contraindications, 
or patients on treatment. The major objection to such restrictions is that if the main aim of 
observational studies is to assess the effectiveness and safety in all patients in routine care 
then restriction inevitably reduces generalizability and representativeness.  
Stratification of populations based on age, sex and major risk factors leads to improved 
accuracy in comparisons while still allowing for inclusion of all patients. There are many 
techniques for modeling and analyzing several variables. Regression analyses use statistical 
modeling to estimate the relationships among variables. It is assumed that parametric 
statistical distributions fit the data. Regressions can adjust for several confounders in the same 
model, but large scale administrative registers might contain hundreds of possible 
confounders. In these cases propensity score stratification is often used to adjust for a large 
number of possible confounders.    
A combination of the above-mentioned strategies is often used in order to reduce 
confounding. A combination of several strategies can also be used to confirm the models 
and/or to explore possible differences in subgroups of interest.  
In study II we had obvious confounding when comparing treatment groups with mortality 
rates being approximately 2-3 times higher in AF-patients with aspirin or no treatment 
compared to warfarin, even after stratification. We therefore refrained from comparing 
treatments and concentrated on exploring the treated populations separately. We focused on 
understanding possible contraindications or complicating co-morbidities in the population on 
aspirin treatment since these patients could be foreseen to become candidates for 
anticoagulant treatment in an era of more aggressive treatment with new treatment 
alternatives.  
In study III a combination of restriction and regression was used, with adjustments for 
possible confounders. We restricted the analysis to AF patients with a definite indication for 
OAC treatment. We also restricted the analysis in time in order to reduce influences from 
changes in regional AF-guidelines since apixaban and dabigatran were recommended in the 
Stockholm region from 2015 onwards. The results were consistent in unadjusted and adjusted 
models. The CHA2DS2VASc-score did not affect treatment persistence. The number of drugs 
claimed 6 months prior to inclusion was used as a measure of frailty and morbidity; and was 
significantly associated with lower persistence.  
In study IV a combination of restriction, stratification and regression was used, with 
adjustments for possible confounders. The results obtained in multiple regression analyses 
were confirmed using two different types of propensity score models. The results were 
consistent in all analyses performed. 
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5.2 MAIN FINDINGS AND INTERPRETATION 
5.2.1 Anticoagulant treatment of AF before the introduction of NOACs 
AF is a chronic disease which to a large extent affects elderly patients with many 
concomitant and sometimes complicating diseases. Primary care plays an important role in 
the antithrombotic treatment of AF; but also in treating hypertension and diabetes which are 
relevant both in the development of AF and included in the CHA2DS2VASc-criteria as risk 
factors for stroke. Lack of diagnoses registered in primary care leads to underestimation of 
CHA2DS2VASc scores and possible overestimation of treatment benefits in low-risk patients.   
Anticoagulants were underused prior to the introduction of NOACs and aspirin was clearly 
overused as stroke prophylaxis. Thus, half of the high-risk AF patients treated with aspirin 
were obvious candidates for OAC treatment with no identified contraindications, a high risk 
for ischemic stroke, a low bleeding risk, and a moderate mortality rate. However, the other 
half of the patients had a high risk for ischemic stroke, but also possible contraindications, a 
high risk for bleeding and a poor prognosis. Conversely, a substantial proportion of AF 
patients with a doubtful indication (i.e. CHA2DS2VASc scores 0-1) received OAC treatment. 
Thus, there were signs of both under- and overuse of effective OAC treatment among AF 
patients in Stockholm before the introduction of NOACs.  
5.2.2 Anticoagulant treatment of AF after the introduction of NOACs 
During the introduction of NOACs the number of patients with a registered diagnosis of AF 
increased considerably in the Stockholm health care region, as did the proportion of OAC-
treated patients. The largest increases of OAC treatment were found in patients with 
complicating co-morbidities and in patients aged 80 years and above. Since 2010 the 
initiations of OAC treatment have increased markedly; from 2012 onwards initiations with 
NOACs have increased steadily while initiations with warfarin have decreased. With the 
possibility to switch between OAC treatments the overall persistence with any OAC was high 
in AF patients. Warfarin and apixaban had higher persistence than dabigatran and 
rivaroxaban. There were indications of better adherence with the once daily regimen of 
rivaroxaban, in contrast to the twice daily regimens of apixaban and dabigatran, when 
measured as proportion of days covered. However, with twice daily regimens (and drugs with 
longer half-lives than rivaroxaban) the therapeutic coverage may be better if patients only 
miss one of the two daily doses. Estimation of adherence with warfarin was not possible due 
to the individual dosing and lack of PT-INR results in the databases.  
NOAC treatment seemed to result in similar or better effectiveness and safety compared to 
warfarin treatment in routine care. NOACs were associated with fewer intracranial bleeds, 
but more gastrointestinal bleeds. The outcomes were similar between NOAC and warfarin 
treatment in high risk patients aged 80 and above and in patients with a prior severe bleed. 
The advantages with NOAC treatment were most pronounced with standard dosing in 
patients under the age of 80, and with dose reductions in patients aged 80 and above. 
There were no significant differences between rivaroxaban or apixaban and warfarin 
treatment. Dabigatran treatment was associated with lower risks of suffering death and 
intracranial bleeds, but a higher risk for gastrointestinal bleeding compared to warfarin. 
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Importantly there were no trends in any of the analyses suggesting that warfarin treatment 
would be better than any of the individual NOACs, either in total or in frail and/or elderly 
patients. 
Taken together these results indicate large improvements in the management of AF in the 
Stockholm Health care region during the introduction of NOACs. NOACs seem to be 
attractive treatments in routine care, but warfarin still plays an important role with over 
20 000 AF patients remaining under treatment in 2015.  
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6 CONCLUSIONS 
In this thesis AF patients and their use of antithrombotic treatments in the Stockholm health 
care region were studied before and after the introduction of NOACs. From the analyses we 
concluded that: 
 Primary care plays an important part in the management of AF in the Stockholm 
health care region  
 Warfarin appeared to be underused and aspirin overused prior to the introduction of 
NOACs, but there were also indications of overuse of anticoagulants in low-risk AF 
patients. 
 Many of the patients without anticoagulant treatment were old, with complicating co-
morbidities, high bleeding risk and a poor prognosis in addition to a high risk of 
ischemic stroke.  
 With the introduction of NOACs the number of patients with an AF diagnosis and the 
proportion of OAC-treated AF patients have increased. The largest increases  in 
treatment were found in patients with complicating co-morbidities and in patients 
aged 80 years and above.   
 The overall treatment  persistence with any OAC was high efter the introduction of 
NOACs. The persistence with warfarin and apixaban was higher than with dabigatran 
and rivaroxaban. 
 NOAC treatment was associated with similar or better effectiveness and safety 
compared to warfarin treatment in routine care. NOACs were associated with fewer 
intracranial bleeds, but more gastrointestinal bleeds.  
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7 PERSPECTIVES 
As illustrated in this thesis there have been considerable changes and most likely also 
improvements regarding stroke prophylaxis in patients with AF after the introduction of 
NOACs. There has been an increased focus on AF and the patients are more often treated 
with anticoagulants. There is now a choice between several OAC treatments facilitating 
individualized treatment. The NOACs are gradually adopted as first line antithrombotic 
treatment in AF patients in specialist care, but also in primary care.  
But the largest increase of OAC treatment can be seen in patients with high risk for both 
stroke and bleeding, leading to increasing demands in the management of these frail patients 
throughout the health care system. The high persistence to OAC treatment is probably in part 
due to active management of bleeding complications and restarting of OAC therapy; which 
might implicate switching of OAC treatment, dose adjustments and other qualified 
considerations. Thus, the availability of the new and apparently easier to use NOACs might 
paradoxically increase the complexity of OAC treatment in AF and raise numerous questions 
that need to be addressed in a specialist setting, possibly by multidisciplinary teams. Another 
possible issue will be the need to centralize warfarin treatment, when fewer and more 
complex patients will be using this demanding treatment.    
Several questions remain for further research. The predictive value of CHA2DS2VASc can 
be discussed and the optimal cut-off level for OAC treatment is still debated. How should 
patients who experience bleeding problems be managed? How should OAC treatment be 
continued after bleeding events? There is limited knowledge on the consequences when 
switching between OACs. Further research is needed to compare outcomes with the different 
treatment alternatives, as well as the outcomes of treatment in relation to persistence and 
adherence in regular health care. Can monitoring of NOACs and individual dose adjustments 
improve results further? How well do the NOACs perform in AF patients with ischemic heart 
disease, in combination with antiplatelet agents, or for patients needing cardioversion? What 
are the bleeding rates of patients interrupting NOACs before surgery or other invasive 
procedures? What are the risks for thromboembolism in these patients? How should NOAC 
treatment best be managed in connection with invasive procedures? Are there other patient 
subgroups in addition to those with mechanical valves in whom warfarin is preferable and 
should be used? Further studies comparing the effectiveness and safety of the individual 
NOACs in routine care are needed. The consequences of the dosing regimens with frequent 
dose reductions of the NOACs should be explored in larger materials. Comparisons of 
outcomes with warfarin and NOAC treatment should also be repeated when NOAC treatment 
is more firmly established and widespread in routine care. Also, it is of interest to perform 
detailed analyses of over- or undertreatment of specific patient categories with OACs.   
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